Kodiak Sciences Inc. (BMV:KOD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 39.21B +877.1% |
| Revenue (ttm) | n/a |
| Net Income | -4.16B |
| EPS | -74.94 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 749.00 |
| Previous Close | 428.00 |
| Day's Range | 749.00 - 749.00 |
| 52-Week Range | 400.00 - 749.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]
News
Kodiak Sciences Transcript: Jefferies Global Healthcare Conference 2026
Three late-stage retinal therapies are advancing, with pivotal phase III data expected in late 2024 and 2026. Zenkuda and KSI-501 aim to combine rapid efficacy with extended durability, while KSI-101 targets a large unmet need in MESI. Multiple BLA filings and potential approvals are anticipated by 2027.
Kodiak Sciences Slides: FY 2026
Kodiak Sciences has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transf...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Kodiak Sciences Earnings release: Q1 2026
Kodiak Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Kodiak Sciences Quarterly report: Q1 2026
Kodiak Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp...
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences Proxy statement: Proxy filing
Kodiak Sciences filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended Decembe...
Kodiak Sciences Annual report: Q4 2025
Kodiak Sciences has published its Q4 2025 annual report on March 31, 2026.
Kodiak Sciences Earnings release: Q4 2025
Kodiak Sciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Kodiak Sciences: Road To $120
Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fu...
Kodiak Sciences stock soars over 60%: what's behind the sharp rally
Shares of Kodiak Sciences surged sharply on Thursday after the biotechnology company reported positive results from a late-stage study of its experimental drug for diabetic retinopathy, a diabetes-rel...
Kodiak Sciences shares surge after eye drug succeeds in late-stage study
Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a late-stage study in patients with diabetes-related eye damage.
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥...
Kodiak Sciences Slides: Corporate presentation
Kodiak Sciences has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2026.
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transf...
Kodiak Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Multiple late-stage retina programs are advancing rapidly, with key data readouts expected in 2024 and 2027. The portfolio targets large unmet needs with differentiated assets, and recent financing ensures funding through major milestones.
Kodiak Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transf...
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran...
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran...
Kodiak Sciences Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing tran...